Market Place
Sourcing Support
Phoenix Molecular Doses First Patient In Ph 2 Dauntless-1 Trial
20 Feb 2025 //
GLOBENEWSWIRE
Fulvestrant API Reducing CO2 footprint by 3.4+ MT/kg
14 Jan 2025 //
PRESS RELEASE
Relay Announces Updated Data for RLY-2608 + Fulvestrant
11 Dec 2024 //
GLOBENEWSWIRE
Scorpion Presents STX-478 Data For Solid Tumors At ESMO Congress 2024
15 Sep 2024 //
BUSINESSWIRE
Relay Therapeutics Announces Positive Data For RLY-2608
09 Sep 2024 //
GLOBENEWSWIRE
Relay Therapeutics Announces Webcast For RLY-2608 Data Report
06 Sep 2024 //
GLOBENEWSWIRE
Texas A&M Health and BurstIQ Partner to Revolutionize Clinical Genomics Research
17 Jul 2024 //
PR NEWSWIRE
Roche’s PI3K inhibitor wins FDA priority review for breast cancer
30 May 2024 //
PHARMACEUTICAL TECHNOLOGY
AZ’s Truqap plus Faslodex receives Japanese approval HR-positive breast cancer
27 Mar 2024 //
INDINPHARMAPOST
Carrick Announces First Patient Dosed in Phase 2b Clinical Trial of Samuraciclib
15 Dec 2023 //
GLOBENEWSWIRE
Roche`s inavolisib combo cuts breast cancer progression by 57%
09 Dec 2023 //
PRESS RELEASE
eFFECTOR Receives U.S. FDA Fast Track Designation for Zotatifin
28 Nov 2023 //
GLOBENEWSWIRE
Astex Earns AstraZeneca Milestone for Truqap Approval
20 Nov 2023 //
CONTRACT PHARMA
TRUQAP™ (capivasertib) plus fulvestrant approved in the US
17 Nov 2023 //
BUSINESSWIRE
US FDA approves AstraZeneca`s breast cancer drug combination
17 Nov 2023 //
REUTERS
NDA Submission Planned EA-114 in Metastatic Breast Cancer Following +ve Type C
30 Aug 2023 //
ONCLIVE
Eugia`s Generic Fulvestrant Receives Approval in the U.S.
30 Jun 2023 //
FDA
SONIA Trial Suggests Second-line Use May Be Optimal for CDK4/6 Inhibitors
25 Jun 2023 //
ONCOLIVE
Capivasertib in combination with FASLODEX granted Priority Review in the US
12 Jun 2023 //
BUSINESSWIRE
eFFECTOR reports interim data updates from cancer combo expansion cohort
26 May 2023 //
CLINICAL TRIALS ARENA
Alembic Pharma gets USFDA nod for generic drug to treat breast cancer
26 Dec 2022 //
ECONOMICTIMES
Alembic`s Generic Fulvestrant Receives Approval in the U.S.
22 Dec 2022 //
FDA
Treadwell Announces Presentation Featuring Trial Update on CFI-402257
09 Dec 2022 //
BIONJ
AstraZeneca hails positive findings in breast cancer drug trial
09 Dec 2022 //
PRESS RELEASE
Pfizer backs $60M infusion into Carrick, teams up on breast cancer treatment
02 Dec 2022 //
ENDPTS
Capivasertib plus FASLODEX improved progression-free survival vs. FASLODEX
26 Oct 2022 //
BUSINESSWIRE
Camizestrant Improved Progression-free Survival Vs. FASLODEX in PII Trial
26 Oct 2022 //
BUSINESSWIRE
Puma Announces Agreement with Takeda for the Development of Alisertib
21 Sep 2022 //
BUSINESSWIRE
Sermonix Announces Results of Phase 2 Study of Lasofoxifene vs. Fulvestrant
13 Sep 2022 //
GLOBENEWSWIRE
Enforcement Report - Week of August 24, 2022
24 Aug 2022 //
FDA
NICE recommends Novartis’ Piqray therapy
14 Jul 2022 //
PHARMATIMES
New Novartis data show Piqray effectiveness across key biomarkers
06 Jun 2022 //
EXPRESS PHARMA
Laekna doses first subjects in Phase Ib/III breast cancer therapy trial
27 May 2022 //
CLINICALTRIALSARENA
Roche hit with another key R&D setback as oral SERD flops in breast cancer
26 Apr 2022 //
FIERCEBIOTECH
Jiangsu Hansoh Pharma`s Generic Fulvestrant Receives Approval in the U.S.
10 Feb 2022 //
FDA
MHRA approves licence extension for Novartis’ targeted therapy for breast cancer
24 Dec 2021 //
PRESS RELEASE
Context Therapeutics® & Wisconsin Oncology Network Announce 1st Patient PhTrial
27 Oct 2021 //
GLOBENEWSWIRE
Cedilla adds $25M to series B to test two cancer drugs in trials
26 Oct 2021 //
FIERCEBIOTECH
Menarini, chased by 3 Big Pharmas, records breast cancer win
22 Oct 2021 //
FIERCEBIOTECH
Enforcement Report - Week of September 29, 2021
29 Sep 2021 //
FDA
Carrick Presents Encouraging data for Samuraciclib in Combo with Fulvestrant
16 Sep 2021 //
GLOBENEWSWIRE
Laekna Therapeutics bags NMPA nod for PIb/III study of afuresertib+fulvestrant
28 Aug 2021 //
PHARMABIZ
FDA fast tracks breast cancer candidate samuraciclib
18 Aug 2021 //
PHARMA TIMES
Dr. Reddy`s announces the launch of Fulvestrant Injection
08 Sep 2020 //
BUSINESS STANDARD
Dr Reddys Lab SA`s Generic Fulvestrant Receives Approval in US
11 Aug 2020 //
FDA
EU regulators approve Novartis` breast cancer combo
30 Jul 2020 //
PHARMA TIMES
Novartis’ Kisquali bests AZ’ Faslodex in breast cancer trial
13 Dec 2019 //
PHARMA TIMES
Pfizer’s Ibrance approved by NICE, to be added to the Cancer Drugs Fund
28 Nov 2019 //
PHARMA FILE
Hbt lab`s Generic Fulvestrant Receives Approval in US
22 Nov 2019 //
FDA
Novartis, Eli Lilly marquee positive survival data for CDK 4/6 franchises
29 Sep 2019 //
ENDPTS
Pii to Manufacture FDA-Approved Hormone Therapy Injection Drug Product
23 Sep 2019 //
PR NEWSWIRE
Mylan launches generic Faslodex inj in US market to treat advanced breast cancer
19 Sep 2019 //
PHARMABIZ
Sagent Pharms`s Generic Fulvestrant Receives Approval in US
27 Aug 2019 //
FDA
Glenmark Pharma`s Generic Fulvestrant Receives Approval in US
27 Aug 2019 //
FDA
FDA Approves Generic Fulvestrant Injection for Advanced Breast Cancer
23 Aug 2019 //
PHARMACYTIMES
Mylan Labs` Generic Fulvestrant Receives Approval in US
27 Jul 2019 //
FDA
NICE U-turn for Kisqali in breast cancer
18 Jul 2019 //
PHARMATIMES
Novartis’ Kisqali, trailing Lilly’s Verzenio, nabs limited NICE backing
17 Jul 2019 //
FIERCE PHARMA
Darzalex, Ibrance among latest SMC decisions
09 Jul 2019 //
PHARMATIMES
Copycats wanted: Pfizer, AZ and more under threat as China solicits generics
21 Jun 2019 //
FIERCE PHARMA
